TY - JOUR
T1 - Management of Kaposi sarcoma after solid organ transplantation
T2 - A European retrospective study
AU - Delyon, Julie
AU - Rabate, Clementine
AU - Euvrard, Sylvie
AU - Harwood, Catherine A.
AU - Proby, Charlotte
AU - Güleç, A. Tülin
AU - Seçkin, Deniz
AU - Del Marmol, Veronique
AU - Bouwes-Bavinck, Jan Nico
AU - Ferrándiz-Pulido, Carla
AU - Ocampo, Maria Andrea
AU - Barete, Stephane
AU - Legendre, Christophe
AU - Francès, Camille
AU - Porcher, Raphael
AU - Lebbe, Celeste
PY - 2019/8
Y1 - 2019/8
N2 - Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these.Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months.Results: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses.Limitations: The retrospective design of the study.Conclusion: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.
AB - Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these.Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months.Results: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses.Limitations: The retrospective design of the study.Conclusion: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.
KW - chemotherapy
KW - immunosuppression
KW - Kaposi sarcoma
KW - mTOR inhibitor
KW - organ transplantation
KW - post-transplant malignancies
UR - http://www.scopus.com/inward/record.url?scp=85067440035&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2019.03.028
DO - 10.1016/j.jaad.2019.03.028
M3 - Article
C2 - 30902727
AN - SCOPUS:85067440035
SN - 0190-9622
VL - 81
SP - 448
EP - 455
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -